Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, First-in-Human, Dose Escalation Trial of MSC2363318A, a Dual p70S6K/Akt Inhibitor, in Subjects With Advanced Malignancies

NCT01971515 is registered in ClinicalTrials.gov with EMD Serono as lead sponsor.

NCT NCT01971515
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01971515 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, First-in-Human, Dose Escalation Trial of MSC2363318A, a Dual p70S6K/Akt Inhibitor, in Subjects With Advanced Malignancies
Lead sponsor
EMD Serono
Phase
Phase 1
Overall status
Completed
Start date
December 13, 2013
Completion date
August 9, 2018
Enrollment
101 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor